CERULEAN PHARMA
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
CERULEAN PHARMA
Industry:
Biotechnology Health Care Nanotechnology Therapeutics
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.darebioscience.com
Total Employee:
11+
Status:
Active
Contact:
(617)494-1544
Email Addresses:
[email protected]
Total Funding:
152.7 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 GoDaddy DNS Facebook Sharer AWS Global Accelerator Akamai Hosted
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Cerulean Pharma
Lux Capital
Lux Capital investment in Private Equity Round - Cerulean Pharma
Bessemer Venture Partners
Bessemer Venture Partners investment in Private Equity Round - Cerulean Pharma
Venrock
Venrock investment in Private Equity Round - Cerulean Pharma
Polaris Partners
Polaris Partners investment in Private Equity Round - Cerulean Pharma
CVF
CVF investment in Private Equity Round - Cerulean Pharma
Lilly Ventures
Lilly Ventures investment in Private Equity Round - Cerulean Pharma
Lux Capital
Lux Capital investment in Series D - Cerulean Pharma
Lilly Ventures
Lilly Ventures investment in Series D - Cerulean Pharma
Venrock
Venrock investment in Series D - Cerulean Pharma
Official Site Inspections
http://www.darebioscience.com
- Host name: 162-144-1-80.unifiedlayer.com
- IP address: 162.144.1.80
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Cerulean Pharma"
About - Daré Bioscience
Jun 18, 2024 We are working hard to identify and advance new therapies that provide additional choices, enhanced outcomes and ease of use for women. By developing and bringing these …See details»
Sabrina Martucci Johnson - Daré Bioscience
Ms. Johnson was honored by Athena, a San Diego-based business organization championing women executives and rising managers in science, technology, …See details»
Daré Bioscience, Inc. | LinkedIn
Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women ...See details»
Daré Bioscience Announces Grant to Support Biotherapeutic …
Jan 17, 2024 Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN DIEGO, Jan. 17, …See details»
Daré Bioscience and Health Decisions Form Strategic Partnership …
May 11, 2020 SAN DIEGO AND DURHAM, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Health …See details»
Daré Bioscience to Present at 2021 BIO Digital | Daré Bioscience
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a …See details»
Press Release - Daré Bioscience
Dec 31, 2021 Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 …See details»
Daré Bioscience, Inc. (DARE) - Yahoo Finance
Find the latest Daré Bioscience, Inc. (DARE) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Daré Bioscience, Inc. (DARE) - Stock Analysis
6 days ago Website https://darebioscience.com. Full Company Profile. Financial Performance. In 2023, Daré Bioscience's revenue was $2.81 million, a decrease of -71.92% compared to the …See details»
Partners - Daré Bioscience
To learn more, please contact us at [email protected]. Daré is solely focused on women’s health. We are advancing a diverse, strategically constructed portfolio of product candidates in contraception, fertility, sexual …See details»
Daré Bioscience Announces Achievement of First Commercial
Oct 16, 2023 To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit …See details»
Daré Bioscience Reports Second Quarter 2024 Financial Results …
Jun 30, 2024 To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit …See details»
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves …
Jan 4, 2024 Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions …See details»
Consumers - Daré Bioscience
We are currently evaluating our product candidates in the clinical trials listed below. Visit this page regularly and subscribe to our email news alerts under the “Email Alerts” tab of the “Investors” …See details»
Press Release - Daré Bioscience
Jan 4, 2024 To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit …See details»
Pipeline - Daré Bioscience
^505(b)(2) regulatory pathway anticipated. ‡DARE-HRT1, DARE-VVA1, and DARE-PDM1 Phase 1 studies conducted in Australia by Daré subsidiary. * As of 4/17/2024.See details»
Daré Bioscience to Present at 2021 BIO Digital - Yahoo Finance
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a …See details»
Daré Bioscience Reports Third Quarter 2021 Financial Results and ...
Sep 30, 2021 Daré Bioscience, Inc. and Subsidiaries: Condensed Consolidated Balance Sheet Data : September 30, 2021 : December 31, 2020 (unaudited) Cash and cash equivalents ...See details»
News - Daré Bioscience
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsSee details»